A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
Geron Corporation
Geron Corporation
Incyte Corporation
PharmaEssentia
Ascentage Pharma Group Inc.
Sierra Oncology LLC - a GSK company
Novartis
Incyte Corporation
Galena Biopharma, Inc.